The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers.

ABSTRACT: Acute lymphoblastic leukemia (ALL) and Chronic lymphocytic leukemia (CLL) are the most common leukemias in children and elderly people, respectively. Standard therapies, such as chemotherapy, are only effective in 40% of ALL adult patients with a five-year survival rate and therefore new alternatives need to be used, such as immunotherapy targeting specific receptors of malignant cells. Among all the options, CAR (Chimeric antigen receptor)-based therapy has arisen as a new opportunity for refractory or relapsed hematological cancer patients. CARs were designed to be used along with T lymphocytes, creating CAR-T cells, but they are presenting such encouraging results that they are already in use as drugs. Nonetheless, their side-effects and the fact that it is not possible to infuse an all

SUBMITTER: Herrera L 

PROVIDER: S-EPMC8582420 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature